ADVERTISEMENT
Therapeutic Advances and Considerations for Treatment Selection in High-Risk AML
In this Oncology Learning Network exclusive virtual roundtable, experts discuss therapeutic advances for hematologic malignancies, with a focus on considerations for treatment selection in patients with high-risk acute myeloid leukemia (AML).
This roundtable took place at the Third Annual Summit of the Americas on Immunotherapies for Hematologic Malignancies and was moderated by Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood and Marrow Transplant and Hematologic Oncology at the Miami Cancer Institute, part of Baptist Health South Florida.
The panel included Richard Stone, MD, Chief of Staff, Dana-Farber Cancer Institute, and Director, Leukemia Division of Medical Oncology Translational Medicine; Robert Soiffer, MD, Chief of Hematologic Malignancies, and Vice Chair of Medical Oncology, Dana-Farber Cancer Institute; and Siddhartha Mukherjee, MD, Professor, Columbia University, Division of Hematology and Oncology, part of the Myelodysplastic Center.
Disclaimer: The views and opinions expressed are those of the author(s) and do not necessarily reflect the official policy or position of Oncology Learning Network or HMP Global, their employees, and affiliates. Any content provided by our bloggers or authors are of their opinion and are not intended to malign any religion, ethnic group, club, association, organization, company, individual, anyone, or anything.
